Liu et al. (2014) demonstrated that FZFA along with cyclophosphamide could restore the ratio of spleen lymphocytes such as CD4+, and their associated cytokines IL-17, Th17, CD4+CD25+, and Foxp3+ Treg cells while inhibiting the inflammatory response. Remarkably, the ratio of Th17 to Treg cells approached normal ranges with this combination. Like FZQJ above, FZFA administered with CTX inhibited tumor growth and metastasis, and could improve survival rates while increasing life span, compared with the administration of CTX alone (Liu et al., 2014). Here, CD4 is linked to neoplasm.